Comparative Evaluation of Different Chitosan Species and Derivatives as Candidate Biomaterials for Oxygen-Loaded Nanodroplet Formulations to Treat Chronic Wounds.
chitosan
chitosan-derivatives
chronic wound
human keratinocytes
nanodroplets
oxygen
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
15 Feb 2021
15 Feb 2021
Historique:
received:
15
01
2021
revised:
08
02
2021
accepted:
11
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
21
5
2021
Statut:
epublish
Résumé
Persistent hypoxia is a main clinical feature of chronic wounds. Intriguingly, oxygen-loaded nanodroplets (OLNDs), filled with oxygen-solving 2H,3H-decafluoropentane and shelled with polysaccharides, have been proposed as a promising tool to counteract hypoxia by releasing a clinically relevant oxygen amount in a time-sustained manner. Here, four different types of chitosan (low or medium weight (LW or MW), glycol-(G-), and methylglycol-(MG-) chitosan) were compared as candidate biopolymers for shell manufacturing. The aim of the work was to design OLND formulations with optimized physico-chemical characteristics, efficacy in oxygen release, and biocompatibility. All OLND formulations displayed spherical morphology, cationic surfaces, ≤500 nm diameters (with LW chitosan-shelled OLNDs being the smallest), high stability, good oxygen encapsulation efficiency, and prolonged oxygen release kinetics. Upon cellular internalization, LW, MW, and G-chitosan-shelled nanodroplets did not significantly affect the viability, health, or metabolic activity of human keratinocytes (HaCaT cell line). On the contrary, MG-chitosan-shelled nanodroplets showed very poor biocompatibility. Combining the physico-chemical and the biological results obtained, LW chitosan emerges as the best candidate biopolymer for future OLND application as a skin device to treat chronic wounds.
Identifiants
pubmed: 33672056
pii: md19020112
doi: 10.3390/md19020112
pmc: PMC7919482
pii:
doi:
Substances chimiques
Biocompatible Materials
0
Chitosan
9012-76-4
Oxygen
S88TT14065
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione Cariplo
ID : HyWonNa project, grant no. 2015-0550
Organisme : Compagnia di San Paolo
ID : Torino_call2014_L2_207
Organisme : Università degli Studi di Torino
ID : ex 60%
Références
Toxicol Appl Pharmacol. 2015 Nov 1;288(3):330-8
pubmed: 26276311
J Control Release. 2014 Aug 10;187:101-17
pubmed: 24878179
Biomacromolecules. 2010 Aug 9;11(8):1897-908
pubmed: 20590156
Skin Pharmacol Physiol. 2010;23(3):117-23
pubmed: 20051712
Int J Nanomedicine. 2020 Dec 03;15:9717-9743
pubmed: 33299313
Eur J Med Chem. 2014 Mar 3;74:169-78
pubmed: 24462847
Biomolecules. 2019 Dec 30;10(1):
pubmed: 31905975
IET Nanobiotechnol. 2019 Oct;13(8):778-785
pubmed: 31625517
Int J Pharm. 2008 Apr 2;353(1-2):139-48
pubmed: 18164151
Am Fam Physician. 2020 Feb 1;101(3):159-166
pubmed: 32003952
J Cell Biol. 1988 Mar;106(3):761-71
pubmed: 2450098
J Wound Care. 2015 Feb;24(2):53-4, 56-60, 62-3
pubmed: 25647433
Int J Pharm. 2009 Aug 13;378(1-2):215-7
pubmed: 19501639
Curr Opin Pharmacol. 2020 Aug;53:117-125
pubmed: 32979727
Expert Opin Drug Deliv. 2019 Jul;16(7):715-740
pubmed: 31215823
Front Bioeng Biotechnol. 2016 Oct 31;4:82
pubmed: 27843895
J Drug Target. 2019 Dec;27(10):1035-1045
pubmed: 30808239
Microbes Infect. 2012 Apr;14(4):311-6
pubmed: 22133978
Annu Int Conf IEEE Eng Med Biol Soc. 2008;2008:2067-70
pubmed: 19163102
Adv Wound Care (New Rochelle). 2020 Jun 2;:
pubmed: 32320364
Surg Clin North Am. 2020 Aug;100(4):681-693
pubmed: 32681869
Adv Drug Deliv Rev. 2019 Jun;146:344-365
pubmed: 29981800
Int J Biol Macromol. 2016 Dec;93(Pt B):1465-1478
pubmed: 27086294
Nano Today. 2017 Aug;15:91-106
pubmed: 29225665
Thyroid. 2016 May;26(5):705-16
pubmed: 26906083
Phys Chem Chem Phys. 2016 Mar 28;18(12):8378-88
pubmed: 26931337
Polymers (Basel). 2018 Feb 22;10(2):
pubmed: 30966247
Curr Pharm Des. 2019;25(15):1682-1693
pubmed: 31269879
Biomaterials. 1998 Aug;19(16):1529-39
pubmed: 9794531
Int J Nanomedicine. 2016 Aug 29;11:4141-55
pubmed: 27621615
Undersea Hyperb Med. 2016 Mar-Apr;43(2):113-22
pubmed: 27265988
Curr Pharm Des. 2017;23(24):3515-3528
pubmed: 28472915
Eur J Pharm Biopharm. 2009 Feb;71(2):257-63
pubmed: 18955137
Methods Mol Biol. 2008;440:15-33
pubmed: 18369934
Pharmacogn Rev. 2016 Jan-Jun;10(19):39-42
pubmed: 27041872
Ther Deliv. 2016;7(2):117-38
pubmed: 26769397
Expert Opin Drug Deliv. 2019 Dec;16(12):1313-1331
pubmed: 31738622
Int J Pharm. 2010 Dec 15;402(1-2):254-7
pubmed: 20888402
Mar Drugs. 2015 Mar 27;13(4):1710-25
pubmed: 25826718
Int Wound J. 2017 Dec;14(6):1276-1289
pubmed: 28799228
Mar Drugs. 2010 Jun 25;8(7):1962-87
pubmed: 20714418
J Colloid Interface Sci. 2003 May 15;261(2):402-10
pubmed: 16256549
Future Microbiol. 2020 Sep;15:1227-1236
pubmed: 33026879
Mar Drugs. 2015 Mar 02;13(3):1133-74
pubmed: 25738328
J Control Release. 2020 Dec 10;328:532-550
pubmed: 32971198
Traffic. 2002 Jul;3(7):443-51
pubmed: 12047552
J Wound Care. 2017 May 1;26(Sup5):S1-S43
pubmed: 28475468
J Nanobiotechnology. 2014 Feb 03;12:5
pubmed: 24491160
Skin Pharmacol Physiol. 2010;23(3):164-70
pubmed: 20110767
Mediators Inflamm. 2015;2015:964838
pubmed: 25878404
Int J Pharm. 2009 Nov 3;381(2):160-5
pubmed: 19616610
PLoS One. 2015 Mar 17;10(3):e0119769
pubmed: 25781463
Int J Pharm. 2017 May 15;523(1):176-188
pubmed: 28330735
J R Soc Interface. 2013 Feb 20;10(82):20120939
pubmed: 23427093
Mol Ther. 2010 Oct;18(10):1787-95
pubmed: 20628361
Pharm Res. 2018 Feb 26;35(4):75
pubmed: 29484487
Eur Rev Med Pharmacol Sci. 2019 Apr;23(2 Suppl):26-37
pubmed: 30977868
Adv Ther. 2017 Mar;34(3):599-610
pubmed: 28108895
Biosci Biotechnol Biochem. 2016;80(3):466-72
pubmed: 26523859
Int J Mol Sci. 2018 May 14;19(5):
pubmed: 29757956
Int J Pharm. 2020 Sep 25;587:119676
pubmed: 32738458
Adv Wound Care (New Rochelle). 2016 Jul 1;5(7):314-328
pubmed: 27366592
Colloids Surf B Biointerfaces. 2016 Sep 1;145:201-207
pubmed: 27182655
Adv Wound Care (New Rochelle). 2014 May 1;3(5):390-399
pubmed: 24804159
Wounds. 2016 Aug;28(8):264-70
pubmed: 27560469
Future Microbiol. 2015;10(6):929-39
pubmed: 26059617
Eur J Pharm Biopharm. 2016 Mar;100:101-8
pubmed: 26792104
Int J Mol Sci. 2016 Dec 11;17(12):
pubmed: 27973441
Toxicol Appl Pharmacol. 2015 Aug 1;286(3):198-206
pubmed: 25937238
Biomacromolecules. 2008 Jul;9(7):1837-42
pubmed: 18540644
J Invest Dermatol. 2001 Jan;116(1):50-6
pubmed: 11168797
Pharm Dev Technol. 2017 Jun;22(4):458-466
pubmed: 26608060